S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
pixel
pixel
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
pixel
pixel
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
pixel
pixel
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
pixel
pixel
Log in
NASDAQ:BGNE

BeiGene Stock Forecast, Price & News

$374.50
+17.51 (+4.90 %)
(As of 01/22/2021 12:00 AM ET)
Add
Compare
Today's Range
$364.01
Now: $374.50
$376.45
50-Day Range
$222.45
MA: $269.41
$362.80
52-Week Range
$118.55
Now: $374.50
$376.45
Volume292,286 shs
Average Volume379,380 shs
Market Capitalization$34.15 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.91
BeiGene, Ltd., a commercial-stage biotechnology company, develops and commercializes molecularly-targeted and immuno-oncology cancer therapeutics in the People's Republic of China, the United States, and internationally. Its commercial products include BRUKINSA to treat R/R mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; ABRAXANE to treat breast cancer; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; KYPROLIS to treat multiple myeloma; BLINCYTO to treat acute lymphocytic leukemia; SYLVANT to treat idiopathic multicentric castleman disease; and QARZIBA to treat neuroblastoma. The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat various lymphomas; Tislelizumab, an anti-PD-1 antibody to treat various solid and hematological cancers; Pamiparib, an inhibitor of PARP1 and PARP2 to treat various solid tumors; Lifirafenib and BGB-3245 to treat various malignancies, such as melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumor. In addition, its clinical stage drug candidates include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; BGB-A1217, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; and BGB-A445, an OX40 agonist antibody to treat solid tumors. The company has collaborations with Celgene Corporation; Merck KGaA; Mirati Therapeutics, Inc.; BioAtla, LLC; Zymeworks, Inc.; Ambrx, Inc.; Atreca Inc.; IGM Biosciences, Inc.; and Hutchison China MediTech Limited. BeiGene, Ltd. was founded in 2010 and is based in Beijing, the People's Republic of China.
BeiGene logo

MarketRank

Overall MarketRank

1.30 out of 5 stars

Medical Sector

684th out of 1,922 stocks

Pharmaceutical Preparations Industry

346th out of 769 stocks

Analyst Opinion: 2.3Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BGNE
CUSIPN/A
Phone1-345-949-4123
Employees3,500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$428.21 million
Book Value$15.87 per share

Profitability

Net Income$-948,630,000.00
Net Margins-569.22%

Miscellaneous

Market Cap$34.15 billion
Next Earnings Date3/1/2021 (Estimated)
OptionableOptionable
$374.50
+17.51 (+4.90 %)
(As of 01/22/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BGNE News and Ratings via Email

Sign-up to receive the latest news and ratings for BGNE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











BeiGene (NASDAQ:BGNE) Frequently Asked Questions

How has BeiGene's stock price been impacted by Coronavirus?

BeiGene's stock was trading at $145.69 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, BGNE stock has increased by 157.1% and is now trading at $374.50.
View which stocks have been most impacted by COVID-19
.

Is BeiGene a buy right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BeiGene in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BeiGene stock.
View analyst ratings for BeiGene
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than BeiGene?

Wall Street analysts have given BeiGene a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but BeiGene wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is John V. Oyler's approval rating as BeiGene's CEO?

21 employees have rated BeiGene CEO John V. Oyler on Glassdoor.com. John V. Oyler has an approval rating of 69% among BeiGene's employees.

When is BeiGene's next earnings date?

BeiGene is scheduled to release its next quarterly earnings announcement on Monday, March 1st 2021.
View our earnings forecast for BeiGene
.

How were BeiGene's earnings last quarter?

BeiGene, Ltd. (NASDAQ:BGNE) posted its quarterly earnings results on Thursday, November, 5th. The company reported ($4.81) EPS for the quarter, missing the Zacks' consensus estimate of ($4.12) by $0.69. The company had revenue of $91.08 million for the quarter, compared to analysts' expectations of $78.50 million. BeiGene had a negative net margin of 569.22% and a negative trailing twelve-month return on equity of 56.81%.
View BeiGene's earnings history
.

What price target have analysts set for BGNE?

8 brokers have issued 1 year target prices for BeiGene's shares. Their forecasts range from $190.00 to $375.00. On average, they expect BeiGene's stock price to reach $259.61 in the next twelve months. This suggests that the stock has a possible downside of 30.7%.
View analysts' price targets for BeiGene
or view Wall Street analyst' top-rated stocks.

Who are some of BeiGene's key competitors?

What other stocks do shareholders of BeiGene own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BeiGene investors own include NVIDIA (NVDA), Alibaba Group (BABA), CRISPR Therapeutics (CRSP), Square (SQ), Intuitive Surgical (ISRG), JD.com (JD), Intel (INTC), Baidu (BIDU), Marvell Technology Group (MRVL) and Cisco Systems (CSCO).

Who are BeiGene's key executives?

BeiGene's management team includes the following people:
  • Mr. John V. Oyler, Co-Founder, Chairman & CEO (Age 52, Pay $1.58M)
  • Dr. Xiaobin Wu Ph.D., GM of China & Pres (Age 58, Pay $1.13M)
  • Dr. Xiaodong Wang, Co-Founder, Chairman of the Scientific Advisory Committee & Non-Exec. Director (Age 57, Pay $4M)
  • Dr. Heng Liang, CFO & Chief Strategy Officer (Age 57, Pay $694.61k)
  • Dr. Jane Edna Huang M.D., Chief Medical Officer of Hematology (Age 47, Pay $705.49k)
  • Mr. Daniel Maller, VP of Fin. & Accounting
  • Mr. Craig West CFA, Sr. Director of Investor Relations
  • Mr. Scott Samuels, Sr. VP & Gen. Counsel
  • Ms. Diana Lee Francis, VP and Global Head of Quality & Regulatory Compliance
  • Mr. Luo Lusong, Head of Discovery Biology & Sr. VP

When did BeiGene IPO?

(BGNE) raised $126 million in an initial public offering (IPO) on Wednesday, February 3rd 2016. The company issued 5,500,000 shares at a price of $22.00-$24.00 per share. Goldman Sachs, Morgan Stanley and Cowen and Company acted as the underwriters for the IPO and Baird was co-manager.

What is BeiGene's stock symbol?

BeiGene trades on the NASDAQ under the ticker symbol "BGNE."

Who are BeiGene's major shareholders?

BeiGene's stock is owned by many different retail and institutional investors. Top institutional investors include Candriam Luxembourg S.C.A. (0.21%), E Fund Management Hong Kong Co. Ltd. (0.01%), Exchange Traded Concepts LLC (0.00%), Crossmark Global Holdings Inc. (0.00%), Redpoint Investment Management Pty Ltd (0.00%) and Kestra Advisory Services LLC (0.00%). Company insiders that own BeiGene stock include Bros Advisors Lp Baker, Donald W Glazer, Howard Liang, Jane Huang, John Oyler, Timothy Yung-Cheng Chen, Xiaobin Wu and Xiaodong Wang.
View institutional ownership trends for BeiGene
.

Which institutional investors are selling BeiGene stock?

BGNE stock was sold by a variety of institutional investors in the last quarter, including MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH, Exchange Traded Concepts LLC, and Crossmark Global Holdings Inc.. Company insiders that have sold BeiGene company stock in the last year include Bros Advisors Lp Baker, Donald W Glazer, Howard Liang, Jane Huang, John Oyler, Timothy Yung-Cheng Chen, Xiaobin Wu, and Xiaodong Wang.
View insider buying and selling activity for BeiGene
or view top insider-selling stocks.

Which institutional investors are buying BeiGene stock?

BGNE stock was acquired by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., E Fund Management Hong Kong Co. Ltd., Redpoint Investment Management Pty Ltd, Kestra Advisory Services LLC, and FNY Investment Advisers LLC.
View insider buying and selling activity for BeiGene
or or view top insider-buying stocks.

How do I buy shares of BeiGene?

Shares of BGNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is BeiGene's stock price today?

One share of BGNE stock can currently be purchased for approximately $374.50.

How big of a company is BeiGene?

BeiGene has a market capitalization of $34.15 billion and generates $428.21 million in revenue each year. The company earns $-948,630,000.00 in net income (profit) each year or ($15.80) on an earnings per share basis. BeiGene employs 3,500 workers across the globe.

What is BeiGene's official website?

The official website for BeiGene is www.beigene.com.

How can I contact BeiGene?

BeiGene's mailing address is 94 SOLARIS AVENUE CAMANA BAY, GRAND CAYMAN E9, KY1-1108. The company can be reached via phone at 1-345-949-4123 or via email at [email protected]

This page was last updated on 1/23/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.